PBMs Keep New Biosimilars on Equal Footing With Best-Selling Humira

Since the first biosimilar for Humira launched in the U.S. this January, it’s been joined by several other biosimilars referencing AbbVie Inc.’s blockbuster immunosuppressive drug — with each manufacturer trying to differentiate their offerings in a suddenly crowded market. Major PBMs Optum Rx and Express Scripts have both responded by adding some of the newly launched biosimilars to their standard commercial formularies, while CVS Caremark appears to be still considering its options.

Experts who spoke with AIS Health, a division of MMIT, shared a variety of viewpoints about how coverage of the newly launched biosimilars is shaping up. But all are closely watching how PBMs, physicians and patients respond to the influx of competition for AbbVie’s cash cow, which has earned the drugmaker $208 billion globally since it was first approved by the FDA in 2002.

© 2024 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

vaccine-needle
June 8

Slew of Adalimumab Biosimilars Expected in July

READ MORE
pharmacists
February 9

Biosimilar Amjevita Wins Spot on Major Formularies, but Humira Proves Tough to Dislodge

READ MORE
nurse-taking-notes
July 13

Coverage of First Humira Biosimilar Varies on ‘Big Three’ PBMs’ Formularies

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today